Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
KGxAuZK3ct0SVq0f
Listen
